Weekend previews of the Monday September 21, 2026 Novo Capital Markets Day in London (webcast live from 09:00 BST / 10:00 CET, running to 15:30 BST / 16:30 CET) landed Saturday and Sunday framing CEO Mike Doustdar's most direct commentary to date on the semaglutide-vs-tirzepatide franchise dynamic. In a Reuters interview released Friday September 18, Doustdar characterized the obesity market as not a 'zero-sum game' as patients 'crave optionality,' rejecting the Morgan Stanley Underweight thesis (September 11 downgrade, DKK 250 target) that Wegovy's U.S. share erosion is structural. Doustdar's 'Novo Way' culture framework announced with the September 14 rebrand emphasizes customer focus, competitiveness, clarity, and care. Sell-side previews (TIKR, Bloomberg, Kontra Invest, TradingKey) frame CMD priorities as: managing the 2031 semaglutide loss of exclusivity, U.S. Wegovy pill script trajectory (>5 million total prescriptions as of August), the CagriSema U.S. obesity decision path (late 2026), the ziltivekimab HERMES/ATHENA terminations, the $1.4 billion Orbis Medicines Sept 17 macrocycle deal, and the Sept 16 Anthropic Claude Science R&D collaboration. NVO shares closed Friday at $42.97 (-0.23% weekly).
Novo (formerly Novo Nordisk; NYSE: NVO; Copenhagen: NOVO-B) confirmed the Capital Markets Day will be held Monday September 21, 2026 in London, webcast live starting 09:00 BST / 10:00 CEST. The event is the first Capital Markets Day under CEO Mike Doustdar and the first outing under the rebranded 'Novo' identity introduced Monday September 14 with the tagline 'Lasting health starts now' and 'The Novo Way' culture framework. Sell-side previews (TIKR, Bloomberg, Kontra Invest) frame the event as a critical reset opportunity following the Friday September 11 Morgan Stanley Underweight downgrade (DKK 250 target), Barclays trim to DKK 300, and HSBC target raise to DKK 320 (Hold). Novo shares trade approximately 32% below the January 2026 52-week high of EUR 54.86. Priorities investors want addressed: the semaglutide 2031 loss of exclusivity, U.S. Wegovy pill script momentum (surpassing 5 million total prescriptions by August), CagriSema's late-2026 U.S. obesity decision path, the ziltivekimab HERMES + ATHENA heart-failure terminations, and how Wednesday's Anthropic Claude Science R&D collaboration and Thursday's $1.4 billion Orbis Medicines macrocycle deal fit the reset narrative.
The U.S. FDA published updated draft guidance for 17 generic peptide products in early September 2026, with the public comment period running through September 28, 2026. The guidance covers testing standards, comparative analytical assessment expectations, and immunogenicity considerations for generic filings of semaglutide, tirzepatide, and 15 other approved peptide products where patents will expire in the coming decade. The 17-peptide update is the most significant FDA generic-peptide policy activity since the 2023 Peptide Guidance Update and lands as the semaglutide patent cliff (2031 loss of exclusivity in major markets) plus tirzepatide's earliest generic entry window (December 2027 for one composition claim, later for others) begin to shape U.S. generic-manufacturer investment decisions. The Indian semaglutide patent expired March 2026, and licensed generics from Biocon, Dr. Reddy's, Sun Pharma, and others followed within weeks; Nomura Research projected the Indian semaglutide generic market at ₹12,000 crore over five years. The FDA guidance is expected to shape U.S. Abbreviated New Drug Application (ANDA) filings post-patent-expiry and represents one of the more consequential regulatory clarifications for peptide biosimilar and generic pathways in years.